Vorinostat - Wikipedia
Vorinostat , [3] also known as suberoylanilide hydroxamic acid (suberoyl+anilide+hydroxamic acid abbreviated as SAHA), is a member of a larger class of compounds that inhibit histone deacetylases (HDAC). Histone deacetylase inhibitors (HDI) have a …
伏立诺他 - 百度百科
2012年7月，媒体报道称研究证实伏立诺他(vorinostat)能够清除病人体内潜伏的 HIV病毒 。 研究人员发现这些接受伏立诺他治疗的患者体内CD4+ T细胞中HIV病毒RNA水平平均增加4.5倍，从而证实HIV病毒被脱去伪装。
从二甲基亚砜到伏立诺他——首个HDAC抑制剂的研发之路 伏立诺他，英文名为Vorinostat…
2018年7月22日 · 伏立诺他，英文名为Vorinostat，商品名为Zolinza®，化学名为Suberoylanilide hydroxamic acid (SAHA)，于 2006年10月26日美国FDA批准上市。用于治疗加重、持续和复发或用两种全身性药物治疗后无效的T细胞淋巴瘤(CTCL, 一种非霍奇金淋巴瘤)。
Vorinostat Uses, Side Effects & Warnings - Drugs.com
2023年12月18日 · Vorinostat is used to treat skin problems caused by cutaneous T-cell lymphoma. Vorinostat is usually given after other treatments did not work or have stopped working. Vorinostat may also be used for purposes not listed in this medication guide.
Vorinostat - NCI - National Cancer Institute
Vorinostat is approved to treat: Cutaneous T-cell lymphoma that has not gotten better, has gotten worse, or has recurred (come back) during or after two systemic therapies . Vorinostat is also being studied in the treatment of other types of cancer .
Vorinostat: Uses, Interactions, Mechanism of Action - DrugBank …
Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or …
伏立诺他 - 维基百科，自由的百科全书
伏立诺他（rINN： Vorinostat ，商品名：Zolinza）是一种含氮有机化合物 [3] ，分子式C 14 H 20 N 2 O 3 ，是一种组蛋白脱乙酰酶 抑制劑。
伏立诺他(Vorinostat) - 药物靶点：HDACs_在研适应症：皮肤T细 …
针对talazoparib（Tal）和vorinostat（Vor）的临床前试验表明两种药物均能够显著抑制PDX肿瘤细胞的生长 总之，本研究首次全面探讨了儿童γδ T-ALL的临床特征和基因分型，并揭示了高危突变的致病机制及潜在的治疗策略。
Vorinostat—An Overview - PMC
Vorinostat is a new drug used in the management of cutaneous T cell lymphoma when the disease persists, gets worse or comes back during or after treatment with other medicines. It is an efficacious and well tolerated drug and has been considered a ...
Vorinostat | C14H20N2O3 | CID 5311 - PubChem
Vorinostat, a histone deacetylase inhibitor, is an antineoplastic agent. The mechanism of the antineoplastic effect of vorinostat has not been fully characterized. Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2, and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations.